Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial
Background Tuberculosis is a major public health problem worldwide. Immunisation with
Mycobacterium bovis BCG vaccine is partially effective in infants, reducing the incidence of …
Mycobacterium bovis BCG vaccine is partially effective in infants, reducing the incidence of …
[引用][C] Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial
MF Cotton, SA Madhi, AK Luabeya, M Tameris… - 2022 - publications.goettingen-research …
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial
MF Cotton, SA Madhi, AK Luabeya… - The Lancet …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Tuberculosis is a major public health problem worldwide. Immunisation with
Mycobacterium bovis BCG vaccine is partially effective in infants, reducing the incidence of …
Mycobacterium bovis BCG vaccine is partially effective in infants, reducing the incidence of …
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial
MF Cotton, SA Madhi, AK Luabeya, M Tameris… - The Lancet Infectious …, 2022 - Elsevier
Background Tuberculosis is a major public health problem worldwide. Immunisation with
Mycobacterium bovis BCG vaccine is partially effective in infants, reducing the incidence of …
Mycobacterium bovis BCG vaccine is partially effective in infants, reducing the incidence of …
[引用][C] Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial
MF Cotton, SA Madhi, AK Luabeya… - The Lancet Infectious …, 2022 - pure.mpg.de
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial.
MF Cotton, SA Madhi, AK Luabeya, M Tameris… - 2022 - cabidigitallibrary.org
Background: Tuberculosis is a major public health problem worldwide. Immunisation with
Mycobacterium bovis BCG vaccine is partially effective in infants, reducing the incidence of …
Mycobacterium bovis BCG vaccine is partially effective in infants, reducing the incidence of …
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial.
MF Cotton, SA Madhi, AK Luabeya… - The Lancet. Infectious …, 2022 - europepmc.org
Background Tuberculosis is a major public health problem worldwide. Immunisation with
Mycobacterium bovis BCG vaccine is partially effective in infants, reducing the incidence of …
Mycobacterium bovis BCG vaccine is partially effective in infants, reducing the incidence of …
[引用][C] Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial
MF Cotton, SA Madhi, AK Luabeya… - Lancet Infectious …, 2022 - pure.mpg.de